Merck and Moderna Announce Positive Phase 3 Results for Intismeran Autogene Plus Pembrolizumab in High-Risk Melanoma – The Babak Lab

The Babak Lab shared on LinkedIn:

“Merck and Moderna have announced positive top-line results from the Phase 3 INTerpath-001 trial of intismeran autogene (V940) + pembrolizumab in patients with resected high-risk melanoma.

Key Results

• The trial included 1,137 patients with resected stage IIB-IV melanoma.
• The combination significantly improved recurrence-free survival (RFS) compared with pembrolizumab alone.
• Distant metastasis-free survival (DMFS) was also significantly improved.
• No new safety signals were reported.

INTerpath-001 is the first positive Phase 3 trial of an individualized neoantigen therapy.

Disclaimer: These are top-line results from an official Merck and Moderna press release. Full INTerpath-001 results are awaiting peer review and publication.

Image generated using Sora by OpenAI.

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma.”

Other articles about melanoma on Oncodaily.